Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6974057 | 1.00 | NR1D1 (0.41) | NR1D1RIPK1PIK3CDMEN1KMT2A | |
| SCHEMBL4301223 | 0.87 | NR1D1 (0.41) | NR1D1KMT2ATDP1GRM2 | |
| SCHEMBL4305832 | 0.87 | S1PR5 (0.41) | NR1D1KMT2AFFAR4ABHD6DAGLA | |
| SCHEMBL3950648 | 0.87 | NR1D1 (0.40) | NR1D1MEN1KMT2ATDP1FFAR4 | |
| SCHEMBL4298176 | 0.87 | NR1D1 (0.40) | NR1D1MEN1KMT2ATDP1FFAR4 | |
| SCHEMBL3948770 | 0.87 | NPC1 (0.42) | TDP1 | |
| SCHEMBL8059551 | 0.83 | CYP1A2 (0.45) | NR1D1RIPK1MEN1KMT2A | |
| SCHEMBL4297028 | 0.80 | SCN3A (0.38) | NR1D1FFAR4 | |
| SCHEMBL6975692 | 0.80 | AGTR2 (0.46) | NR1D1RIPK1PIK3CDABHD6DAGLA | |
| SCHEMBL22555190 | 0.80 | AGTR2 (0.46) | NR1D1RIPK1PIK3CDABHD6DAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| WO-2009026197-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | CTSB, CTSS, CTSF | NR1D1 1663/4885RIPK1 3303/4885PIK3CD 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.